- The Washington Times - Wednesday, November 5, 2008

TRENTON, N.J. (AP) - French drugmaker Sanofi-Aventis is halting all research on a once-promising diet drug that never made it to the U.S. market.

The company says it is stopping all ongoing human testing of the drug, Accomplia, which until recently was sold in Europe.

Sanofi-Aventis says in a statement the decision is being made “in light of recent demands by certain national health authorities.”

Just two weeks ago, the company suspended sales of Accomplia in Europe. That was done because health authorities there said the drug’s risks outweighed its benefits.

Those risks include depression, anxiety and stress disorders.

In this country, the Food and Drug Administration rejected the drug, saying it increased risk of suicidal thoughts.

Copyright © 2018 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.

 

Click to Read More and View Comments

Click to Hide